Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer in vitro and in vivo
碩士 === 國立交通大學 === 分子醫學與生物工程研究所 === 104 === Background: Vorinostat, a histone deacetylase (HDAC) inhibitor, is a promising agent for cancer therapy. Combining vorinostat with cisplatin may relax the chromatin structure and facilitate the accessibility of cisplatin, thus enhancing its cytotoxicity. St...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2016
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/4b94b8 |